The Impact of Using a Non-motorised Physical Assistance Device on the Prevention of Musculoskeletal Disorders Amongst Care-givers (TM2S)

November 12, 2026 updated by: Pôle Saint Hélier

This experimental study uses a Single-Case Experimental Design (SCED) with multiple baselines across participants to evaluate the impact of a non motorized assistive device (DAP) on muscle effort in care givers during their professional activities. Each participant completes a 12-day protocol consisting of three phases (A1 - B - A2), with the initial baseline (A1, no device) randomized between 2 and 6 days, followed by a 6-day intervention phase (B, wearing the non-motorized DAP), and a final withdrawal phase (A2, no device) adjusted to complete the 12-day period. Muscle effort is continuously quantified as a percentage of maximum voluntary contraction using mechanomyographic sensors (MOTEN Technologies) placed on the lumbar and biceps muscles, as well as the quadriceps at the Fondation Saint-Hélier site.

Study Overview

Status

Not yet recruiting

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

9

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

      • Landivisiau, France
        • Fondation Ildys - EHPAD Saint Vincent
        • Contact:
        • Principal Investigator:
          • Sylvia Courtes
      • Ploemeur, France, 56270
        • Centre Mutualiste de Rééducation et de Réadaptation Fonctionnelles (CMRRF) de Kerpape
        • Contact:
        • Principal Investigator:
          • Cécile Diot
      • Rennes, France

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Aged 18 years and older.
  • Height between 160 cm and 200 cm.
  • Professional care-giver working in SMR (Medical and Rehabilitation Care) or medico-social departments of partner healthcare facilities.
  • Willing to wear the non-motorized DAP under the conditions defined by the protocol.
  • Affiliated with or beneficiary of a national social security scheme.
  • Having provided free and informed written consent.

Exclusion Criteria:

  • Self-reported back, leg, or knee pathology that raises doubts regarding the safe use of the non-motorized DAP without prior medical clearance.
  • Pregnant, parturient, or breastfeeding women.
  • Persons deprived of liberty by a judicial or administrative decision (including legal guardianship, trusteeship, or court protection).
  • Persons receiving psychiatric care or admitted to a healthcare or social establishment for reasons other than research.
  • Persons in emergency situations unable to express prior informed consent.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Non-motorized DAP Intervention

Single group following a 12-day A1-B-A2 SCED protocol. Participants undergo a randomized baseline of 2-6 days without the device (A1), a 6-day intervention phase wearing the non-motorized DAP during work activities (B), and an adjusted withdrawal phase without the device (A2).

Participants wear a non-motorized device for posture assistance (DAP) during their regular professional activities as nurse's aides for 6 consecutive days (Phase B of the 12-day A1-B-A2 SCED protocol). Muscle effort is continuously monitored using mechanomyographic sensors (MOTEN Technologies).

Other Names:
  • Non-motorized posture-assistive device
  • Physical assistance device

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Percentage of Maximum Voluntary Contraction (% MVC) of target muscle groups
Time Frame: Daily during work hours over the 12-day study protocol

Muscle effort is continuously quantified via mechanomyography (MMG) using MOTEN Technologies sensors. The primary outcome is the muscle effort level expressed as a percentage of the individual's maximum voluntary contraction (% MVC) for each monitored muscle group (lumbar and biceps muscles across all sites; quadriceps muscles at the Fondation Saint-Hélier site). Measures are compared across the baseline (A1), intervention (B), and withdrawal (A2) phases.

Daily during work hours over the 12-day study protocol

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in postural strain measured by mechanomyography (MMG)
Time Frame: Daily during work hours over the 12-day study protocol

Postural strain during daily professional activities is evaluated using mechanomyographic (MMG) sensors (MOTEN Technologies) placed on target muscle groups. Measures are compared across the baseline (A1), intervention (B), and withdrawal (A2) phases.

Daily during work hours over the 12-day study protocol
Change in perceived effort score using a Numerical Rating Scale (NRS)
Time Frame: Twice daily (after each half-day work shift) over the 12-day study protocol

Perceived exertion during work tasks is assessed using a 0 to 10 Numerical Rating Scale (NRS/EVN), where 0 represents very low effort and 10 represents very high effort.

Twice daily (after each half-day work shift) over the 12-day study protocol
Change in perceived fatigue score using a Numerical Rating Scale (NRS)
Time Frame: Twice daily (before and after each full work day) over the 12-day study protocol

Subjective physical fatigue is assessed using a 0 to 10 Numerical Rating Scale (NRS/EVN), where 0 represents very low fatigue and 10 represents very high fatigue.

Twice daily (before and after each full work day) over the 12-day study protocol
User satisfaction score with the non-motorized DAP (ESAT questionnaire)
Time Frame: At the end of Phase B (Day 6 of wearing the device)

User satisfaction with the assistive device will be assessed using the 8-item Device subscale of the Quebec User Evaluation of Satisfaction with Assistive Technology (QUEST 2.0 / ESAT). Items are rated on a 5-point Likert scale from 1 to 5, yielding a total sum score ranging from 8 to 40, where higher scores indicate greater satisfaction

At the end of Phase B (Day 6 of wearing the device)
Acceptability score based on the UTAUT model
Time Frame: Baseline (prior to Phase A1/B) and Post-Intervention (At the end of day 6 of phase B)

Technology acceptance will be assessed across the constructs of the Unified Theory of Acceptance and Use of Technology (UTAUT) questionnaire. Each item is rated on a 7-point Likert scale from 1 (strongly disagree) to 7 (strongly agree). Each item also belongs one of several subscales. Mean scores are calculated separately for each subscale, ranging from 1 to 7, where higher scores indicate greater technology acceptance.

Baseline (prior to Phase A1/B) and Post-Intervention (At the end of day 6 of phase B)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

November 1, 2026

Primary Completion (Estimated)

November 1, 2027

Study Completion (Estimated)

December 1, 2027

Study Registration Dates

First Submitted

November 5, 2026

First Submitted That Met QC Criteria

November 12, 2026

First Posted (Actual)

November 17, 2026

Study Record Updates

Last Update Posted (Actual)

November 17, 2026

Last Update Submitted That Met QC Criteria

November 12, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2026-A01360-51

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe